AR090583A1 - Formulacion liquida de conjugados de la hormona de crecimiento humana de accion prolongada, altamente concentrada - Google Patents
Formulacion liquida de conjugados de la hormona de crecimiento humana de accion prolongada, altamente concentradaInfo
- Publication number
- AR090583A1 AR090583A1 ARP130101078A AR090583A1 AR 090583 A1 AR090583 A1 AR 090583A1 AR P130101078 A ARP130101078 A AR P130101078A AR 090583 A1 AR090583 A1 AR 090583A1
- Authority
- AR
- Argentina
- Prior art keywords
- human
- human growth
- conjugates
- liquid formulation
- highly concentrated
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract 2
- 230000002035 prolonged effect Effects 0.000 title 1
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 4
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 4
- 239000000854 Human Growth Hormone Substances 0.000 abstract 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000007951 isotonicity adjuster Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000006174 pH buffer Substances 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Formulación líquida de conjugados de la hormona de crecimiento humana de acción prolongada, altamente concentrada, que comprende una cantidad farmacéuticamente eficaz del conjugado de la hormona de crecimiento humana de acción prolongada en donde la hormona de crecimiento humana (hGH) está unida a una región Fc de inmunoglobulina, y un estabilizante sin albúmina, donde dicho estabilizante comprende un amortiguador del pH, un agente tensioactivo no iónico, un alcohol de azúcar y cloruro de sodio como agente isotónico, y un método para preparar la misma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120033580 | 2012-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR090583A1 true AR090583A1 (es) | 2014-11-19 |
Family
ID=49260722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101078 AR090583A1 (es) | 2012-03-30 | 2013-04-03 | Formulacion liquida de conjugados de la hormona de crecimiento humana de accion prolongada, altamente concentrada |
Country Status (9)
Country | Link |
---|---|
US (2) | US10064951B2 (es) |
EP (1) | EP2830649B1 (es) |
JP (2) | JP6386441B2 (es) |
KR (1) | KR20130111462A (es) |
AR (1) | AR090583A1 (es) |
DK (1) | DK2830649T3 (es) |
ES (1) | ES2713979T3 (es) |
TW (1) | TWI617324B (es) |
WO (1) | WO2013147559A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
BR112016006455A2 (pt) | 2013-09-27 | 2017-08-01 | Hanmi Pharm Ind Co Ltd | ?formulação de conjugado de hormônio de crescimento humano de ação prolongada? |
SG11201608120TA (en) * | 2014-03-31 | 2016-11-29 | Hanmi Pharm Ind Co Ltd | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage |
KR20170079409A (ko) * | 2015-12-30 | 2017-07-10 | 한미약품 주식회사 | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 |
JP6892563B1 (ja) * | 2020-05-01 | 2021-06-23 | HOYA Technosurgical株式会社 | 帯電物質の精製方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8504099D0 (en) | 1985-02-18 | 1985-03-20 | Wellcome Found | Physiologically active substances |
US5981485A (en) * | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
US5763394A (en) * | 1988-04-15 | 1998-06-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5374620A (en) * | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
SE9201073D0 (sv) | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
CA2489978A1 (en) | 1992-07-31 | 1994-02-17 | Genentech, Inc. | Human growth hormone aqueous formulation |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
AUPN801296A0 (en) * | 1996-02-12 | 1996-03-07 | Csl Limited | Stabilised growth hormone formulation and method of preparation thereof |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US7001892B1 (en) * | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
US6646899B2 (en) * | 2001-09-21 | 2003-11-11 | Broadcom Corporation | Content addressable memory with power reduction technique |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
BRPI0408946A (pt) | 2003-03-28 | 2006-04-04 | Biopolymed Inc | material biologicamente ativo conjugado com polìmero biocompatìvel com complexo 1:1, seu processo de preparação e composição farmacêutica compreendendo o mesmo |
US20050281778A1 (en) | 2003-03-28 | 2005-12-22 | Myung-Ok Park | Human growth hormone conjugated with biocompatible polymer |
US7608270B2 (en) * | 2003-06-27 | 2009-10-27 | University Of Hull | Dosage form |
ES2438098T3 (es) * | 2003-11-13 | 2014-01-15 | Hanmi Science Co., Ltd. | Composición farmacéutica que comprende un Fc de inmunoglobulina como vehículo |
WO2005063298A1 (en) * | 2003-12-23 | 2005-07-14 | Pharmacia Corporation | Stable growth hormone liquid formulation |
CA2618068C (en) * | 2005-08-05 | 2016-02-16 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
EP2461831B1 (en) * | 2009-08-06 | 2018-11-21 | Novo Nordisk Health Care AG | Growth hormones with prolonged in-vivo efficacy |
KR101337797B1 (ko) | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
WO2012068779A1 (zh) | 2010-11-24 | 2012-05-31 | Cai Yinglin | 淋浴热水用热能交换装置 |
-
2013
- 2013-03-23 US US14/383,820 patent/US10064951B2/en not_active Expired - Fee Related
- 2013-03-29 TW TW102111362A patent/TWI617324B/zh not_active IP Right Cessation
- 2013-03-29 KR KR20130034845A patent/KR20130111462A/ko not_active Application Discontinuation
- 2013-03-29 WO PCT/KR2013/002660 patent/WO2013147559A1/en active Application Filing
- 2013-03-29 JP JP2015503126A patent/JP6386441B2/ja not_active Expired - Fee Related
- 2013-03-29 EP EP13769126.7A patent/EP2830649B1/en not_active Not-in-force
- 2013-03-29 ES ES13769126T patent/ES2713979T3/es active Active
- 2013-03-29 DK DK13769126.7T patent/DK2830649T3/en active
- 2013-04-03 AR ARP130101078 patent/AR090583A1/es unknown
-
2018
- 2018-02-22 JP JP2018029313A patent/JP2018115166A/ja not_active Ceased
- 2018-07-25 US US16/045,511 patent/US20180344866A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20150118255A1 (en) | 2015-04-30 |
JP2015514704A (ja) | 2015-05-21 |
JP2018115166A (ja) | 2018-07-26 |
DK2830649T3 (en) | 2019-03-25 |
JP6386441B2 (ja) | 2018-09-05 |
WO2013147559A1 (en) | 2013-10-03 |
EP2830649A1 (en) | 2015-02-04 |
US10064951B2 (en) | 2018-09-04 |
US20180344866A1 (en) | 2018-12-06 |
KR20130111462A (ko) | 2013-10-10 |
EP2830649B1 (en) | 2018-12-05 |
TW201343198A (zh) | 2013-11-01 |
TWI617324B (zh) | 2018-03-11 |
EP2830649A4 (en) | 2015-08-05 |
ES2713979T3 (es) | 2019-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR113034A2 (es) | Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado | |
AR090583A1 (es) | Formulacion liquida de conjugados de la hormona de crecimiento humana de accion prolongada, altamente concentrada | |
AR091902A1 (es) | Formulacion liquida de un conjugado de insulina de accion prolongada | |
CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
AR121939A2 (es) | Composición líquida de un conjugado derivado de oxintomodulina de larga duración y procedimiento para prepararla | |
AR108936A2 (es) | Formulación subcutánea de anticuerpo anti-her2 | |
MX2015001217A (es) | Formulacion liquida de insulina de accion prolongada y de peptido insulinotropico. | |
AR097791A1 (es) | Formulaciones de anticuerpos anti-pdl1 | |
AR094821A1 (es) | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada | |
PE20191815A1 (es) | Formulaciones acuosas estables de adalimumab | |
AR095396A1 (es) | Formulaciones de anticuerpo | |
PE20142407A1 (es) | Formulacion de anticuerpos | |
PE20151425A1 (es) | Formulaciones farmaceuticas muy concentradas que comprenden un anticuerpo anti-cd20 | |
NZ628398A (en) | Stable preservative-free mydriatic and anti-inflammatory solutions for injection | |
MX2015015152A (es) | Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13. | |
BR112016006455A2 (pt) | ?formulação de conjugado de hormônio de crescimento humano de ação prolongada? | |
AR086872A1 (es) | Composicion descongelante, proceso de preparacion, conjunto de partes y uso | |
AR082776A1 (es) | Estabilizacion de hormona foliculo estimulante (fsh) | |
AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
AR098386A1 (es) | Formulación para gonadotropinas | |
AR107276A1 (es) | Una formulación líquida de conjugado de hormona del crecimiento humana de acción prolongada | |
AR087811A1 (es) | Vacuna contra el staphylococcus aureus | |
IN2013MU03544A (es) | ||
TH138064A (th) | สูตรตำรับแอนทิบอดีแอนทิ-her2 ใต้หนัง |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |